|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |
| Brief Title † | The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients |
| Official Title † | A Multi-Center Trial to Evaluate the Safety and Effectiveness of Peridex Dosed Twice or Three Times Daily for Preventing or Delaying the Occurrence of Lesions Due to Oral Candidiasis in HIV-Positive Individuals |
| Brief Summary | To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients, who are at risk of the disease based on previous history of candidiasis. |
| Detailed Description | |
| Study Phase | |
| Study Type † | Interventional |
| Study Design † | Treatment, Dose Comparison |
| Primary Outcome Measure † | |
| Secondary Outcome Measure † | |
| Condition † | Candidiasis, Oral HIV Infections |
| Intervention † | Drug: Chlorhexidine gluconate |
| MEDLINE PMIDs | 7936591 |
| Links | |
| Recruitment Information Fields | |
| Recruitment Status † | Completed |
| Enrollment † | |
| Start Date † | |
| Completion Date | |
| Eligibility Criteria † | Inclusion Criteria Prior Medication: Allowed within 6 months of study entry:
Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded:
Concurrent Medication: Excluded:
Concurrent Treatment: Excluded:
Patients with the following are excluded:
Prior Medication: Excluded within 7 days of study entry:
Prior Treatment: Excluded within 2 weeks of starting study drug:
Patients must be:
|
| Gender | Both |
| Ages | 13 Years to 75 Years |
| Accepts Healthy Volunteers | No |
| Contacts †† | |
| Location Countries † | United States |
| Administrative Information Fields | |
| NCT ID † | NCT00002431 |
| Organization ID | 050A |
| Secondary IDs †† | CC-220 |
| Study Sponsor † | Procter and Gamble |
| Collaborators †† | |
| Investigators † | |
| Information Provided By | NIH AIDS Clinical Trials Information Service |
| Verification Date | November 1993 |
| First Received Date † | November 2, 1999 |
| Last Updated Date | June 23, 2005 |